Hedge Fund - Palo Alto Investors
Biomarin Pharmaceutical Inc (BMRN)
Holding History Records
| No. | Filing Period | Value | % of Portfolio | Number of Shares | Avg. Quarterly Share Price |
|---|---|---|---|---|---|
| 1 | 2023 - Q4 (2023-12-31) | $144,702,219 | 13.03% | 1,500,749 | $88.47 |
| 2 | 2023 - Q3 (2023-09-30) | $162,009,977 | 15.32% | 1,831,035 | $88.98 |
| 3 | 2023 - Q2 (2023-06-30) | $158,714,114 | 12.82% | 1,831,035 | $94.11 |
| 4 | 2023 - Q1 (2023-03-31) | $178,049,843 | 14.75% | 1,831,035 | $103.67 |
| 5 | 2022 - Q4 (2022-12-31) | $195,162,580 | 16.63% | 1,885,811 | $93.88 |
| 6 | 2022 - Q3 (2022-09-30) | $167,528,000 | 13.24% | 1,976,265 | $89.04 |
| 7 | 2022 - Q2 (2022-06-30) | $170,826,000 | 14.88% | 2,061,373 | $79.62 |
| 8 | 2022 - Q1 (2022-03-31) | $164,964,000 | 12.75% | 2,139,614 | $83.67 |
| 9 | 2021 - Q4 (2021-12-31) | $195,514,000 | 12.49% | 2,212,950 | $82.51 |
| 10 | 2021 - Q3 (2021-09-30) | $171,039,000 | 10.32% | 2,212,950 | $78.90 |
| 11 | 2021 - Q2 (2021-06-30) | $184,649,000 | 10.17% | 2,212,950 | $79.27 |
| 12 | 2021 - Q1 (2021-03-31) | $166,556,000 | 9.48% | 2,205,750 | $81.69 |
| 13 | 2020 - Q4 (2020-12-31) | $188,976,000 | 9.9% | 2,155,050 | $79.28 |
| 14 | 2020 - Q3 (2020-09-30) | $131,812,000 | 7.23% | 1,732,550 | $101.18 |
| 15 | 2020 - Q2 (2020-06-30) | $173,410,000 | 10.41% | 1,405,950 | $99.39 |
| 16 | 2020 - Q1 (2020-03-31) | $130,482,000 | 10.92% | 1,544,163 | $86.16 |
| 17 | 2019 - Q4 (2019-12-31) | $170,887,000 | 9.4% | 2,021,136 | $75.53 |
| 18 | 2019 - Q3 (2019-09-30) | $148,921,000 | 9.91% | 2,209,504 | $77.02 |
| 19 | 2019 - Q2 (2019-06-30) | $223,245,000 | 10.85% | 2,606,485 | $85.55 |
| 20 | 2019 - Q1 (2019-03-31) | $234,643,000 | 9.78% | 2,641,485 | $92.68 |
| 21 | 2018 - Q4 (2018-12-31) | $217,961,000 | 11.6% | 2,559,733 | $95.13 |
| 22 | 2018 - Q3 (2018-09-30) | $247,218,000 | 9.99% | 2,549,431 | $99.82 |
| 23 | 2018 - Q2 (2018-06-30) | $240,156,000 | 9.59% | 2,549,431 | $87.57 |
| 24 | 2018 - Q1 (2018-03-31) | $206,362,000 | 8.82% | 2,545,482 | $85.82 |
| 25 | 2017 - Q4 (2017-12-31) | $222,729,000 | 9.59% | 2,497,806 | $86.95 |
| 26 | 2017 - Q3 (2017-09-30) | $226,953,000 | 9.55% | 2,438,519 | $88.36 |
| 27 | 2017 - Q2 (2017-06-30) | $216,580,000 | 10.11% | 2,384,719 | $90.98 |
| 28 | 2017 - Q1 (2017-03-31) | $209,146,000 | 9.88% | 2,382,619 | $88.96 |
| 29 | 2016 - Q4 (2016-12-31) | $162,385,000 | 9.26% | 1,960,219 | $86.00 |
| 30 | 2016 - Q3 (2016-09-30) | $165,694,000 | 9.62% | 1,790,899 | $94.17 |
| 31 | 2016 - Q2 (2016-06-30) | $135,170,000 | 10.2% | 1,737,399 | $85.01 |
| 32 | 2016 - Q1 (2016-03-31) | $110,552,000 | 8.58% | 1,340,347 | $81.36 |
| 33 | 2015 - Q4 (2015-12-31) | $140,048,000 | 7.79% | 1,336,847 | $104.32 |
| 34 | 2015 - Q3 (2015-09-30) | $175,515,000 | 8.43% | 1,666,492 | $133.58 |
| 35 | 2015 - Q2 (2015-06-30) | $227,067,000 | 10.09% | 1,660,092 | $123.92 |
| 36 | 2015 - Q1 (2015-03-31) | $205,597,000 | 10.16% | 1,649,792 | $105.95 |
| 37 | 2014 - Q4 (2014-12-31) | $117,719,000 | 6.91% | 1,302,197 | $83.16 |
| 38 | 2014 - Q3 (2014-09-30) | $91,239,000 | 6.81% | 1,264,397 | $65.72 |
| 39 | 2014 - Q2 (2014-06-30) | $56,959,000 | 4.24% | 915,587 | $60.41 |
| 40 | 2014 - Q1 (2014-03-31) | $50,863,000 | 4.2% | 745,687 | $73.70 |
| 41 | 2013 - Q4 (2013-12-31) | $52,135,000 | 4.86% | 741,087 | $67.90 |
| 42 | 2013 - Q3 (2013-09-30) | $40,725,000 | 4.27% | 564,287 | $66.46 |
| 43 | 2013 - Q2 (2013-06-30) | $43,874,000 | 5.17% | 787,119 | $62.32 |
| 44 | 2013 - Q1 (2013-03-31) | $48,857,000 | 5.78% | 784,719 | $56.63 |
| 45 | 2012 - Q4 (2012-12-31) | $45,721,000 | 5.35% | 929,285 | $45.56 |
| 46 | 2012 - Q3 (2012-09-30) | $36,777,000 | 3.62% | 913,485 | $39.29 |
| 47 | 2012 - Q1 (2012-03-31) | $43,826,000 | 4.8% | 1,279,585 | $35.67 |
| 48 | 2011 - Q4 (2011-12-31) | $43,566,000 | 4.88% | 1,267,185 | $32.81 |
| 49 | 2011 - Q3 (2011-09-30) | $39,611,000 | 5.11% | 1,242,887 | $29.05 |
| 50 | 2011 - Q2 (2011-06-30) | $33,302,000 | 3.45% | 1,223,887 | $26.32 |
The displayed share prices are average quarterly stock market prices.